IOVANCE BIOTHERAPEUTICS, INC. 8-K

What Happened

• Iovance Biotherapeutics, Inc. filed an 8-K on January 9, 2026, updating its corporate presentation used for conferences and analyst and investor outreach. The presentation states the company expects to achieve its previously disclosed full-year 2025 revenue guidance of $250 million to $300 million in the first full calendar year of Amtagvi sales. The updated presentation is attached as Exhibit 99.1 to the filing.

Key Details

• Filed on: January 9, 2026 (Form 8-K, Item 8.01 disclosure).
• Revenue guidance: Company expects full-year 2025 revenue of $250–$300 million.
• Driver: Guidance tied to Amtagvi — described as the first full calendar year of Amtagvi sales.
• Presentation: Corporate presentation updated and included as Exhibit 99.1.

Why It Matters

• This update reiterates management’s revenue expectations for 2025 and ties near-term financial outlook directly to commercial sales of Amtagvi. For investors, the $250–$300M range is a concrete benchmark to compare against future quarterly results and market expectations. The attached presentation provides the company’s messaging and may be used at upcoming conferences and analyst meetings, which can influence analyst models and market sentiment.